Kenneth Pienta

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. doi request reprint Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
    Kenneth J Pienta
    University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Room 7308, Ann Arbor, MI, 48109, USA
    Invest New Drugs 31:760-8. 2013
  2. pmc Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles
    Kun Wan Chen
    Department of Internal Medicine, The University of Michigan, 7308 CCC, 1500 E, Medical Center Drive, Ann Arbor, MI 48109, USA
    Theor Biol Med Model 8:36. 2011
  3. pmc Successfully accelerating translational research at an academic medical center: the University of Michigan-Coulter translational research partnership program
    Kenneth J Pienta
    The Michigan Institute for Clinical Research, The University of Michigan, Ann Arbor, Michigan, USA
    Clin Transl Sci 3:316-8. 2010
  4. doi request reprint Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later
    Kenneth J Pienta
    Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Urology 73:S11-20. 2009
  5. ncbi request reprint Etoposide in prostate cancer
    J M Kamradt
    University of Michigan Medical Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Expert Opin Pharmacother 1:271-5. 2000
  6. ncbi request reprint A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)
    K J Pienta
    University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Prostate 46:257-61. 2001
  7. ncbi request reprint Mechanisms underlying the development of androgen-independent prostate cancer
    Kenneth J Pienta
    Michigan Urology Center, University of Michigan, Ann Arbor, Michigan 48109 0946, USA
    Clin Cancer Res 12:1665-71. 2006
  8. ncbi request reprint The "emigration, migration, and immigration"of prostate cancer
    Kenneth J Pienta
    University of Michigan Urology Center, Ann Arbor, MI 48109 0946, USA
    Clin Prostate Cancer 4:24-30. 2005
  9. ncbi request reprint Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy
    Kenneth J Pienta
    Department of Internal Medicine, Michigan Urology Center, University of Michigan School of Medicine, Ann Arbor, Michigan 48109 0946, USA
    Urology 62:95-101. 2003
  10. pmc The current state of preclinical prostate cancer animal models
    Kenneth J Pienta
    University of Michigan, Department of Internal Medicine, Ann Arbor, MI, USA
    Prostate 68:629-39. 2008

Research Grants

Collaborators

Detail Information

Publications90

  1. doi request reprint Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
    Kenneth J Pienta
    University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Room 7308, Ann Arbor, MI, 48109, USA
    Invest New Drugs 31:760-8. 2013
    ..Conclusion Carlumab was well-tolerated but did not block the CCL2/CCR2 axis or show antitumor activity as a single agent in metastatic CRPC...
  2. pmc Modeling invasion of metastasizing cancer cells to bone marrow utilizing ecological principles
    Kun Wan Chen
    Department of Internal Medicine, The University of Michigan, 7308 CCC, 1500 E, Medical Center Drive, Ann Arbor, MI 48109, USA
    Theor Biol Med Model 8:36. 2011
    ..Proliferation in the new site has an impact on the target organ microenvironment (ecological impact) and eventually the human host (biosphere impact)...
  3. pmc Successfully accelerating translational research at an academic medical center: the University of Michigan-Coulter translational research partnership program
    Kenneth J Pienta
    The Michigan Institute for Clinical Research, The University of Michigan, Ann Arbor, Michigan, USA
    Clin Transl Sci 3:316-8. 2010
    ..The University of Michigan (UM) has partnered with the Wallace H. Coulter Foundation (CF) to create a model providing an infrastructure to overcome these risks. This model is easily adoptable to other academic medical centers (AMCs)...
  4. doi request reprint Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later
    Kenneth J Pienta
    Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    Urology 73:S11-20. 2009
    ..Although it has its limitations, PSA still remains the best-studied marker for the detection of PCa...
  5. ncbi request reprint Etoposide in prostate cancer
    J M Kamradt
    University of Michigan Medical Center, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Expert Opin Pharmacother 1:271-5. 2000
    ....
  6. ncbi request reprint A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407)
    K J Pienta
    University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Prostate 46:257-61. 2001
    ..This study tested this regimen in a multi-institutional setting...
  7. ncbi request reprint Mechanisms underlying the development of androgen-independent prostate cancer
    Kenneth J Pienta
    Michigan Urology Center, University of Michigan, Ann Arbor, Michigan 48109 0946, USA
    Clin Cancer Res 12:1665-71. 2006
  8. ncbi request reprint The "emigration, migration, and immigration"of prostate cancer
    Kenneth J Pienta
    University of Michigan Urology Center, Ann Arbor, MI 48109 0946, USA
    Clin Prostate Cancer 4:24-30. 2005
    ..This review describes the steps of metastasis using a paradigm of emigration to migration to immigration, with prostate cancer as a model system...
  9. ncbi request reprint Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy
    Kenneth J Pienta
    Department of Internal Medicine, Michigan Urology Center, University of Michigan School of Medicine, Ann Arbor, Michigan 48109 0946, USA
    Urology 62:95-101. 2003
    ..The rationale behind Radiation Therapy Oncology Group (RTOG) P-0014 is to demonstrate in a randomized phase 3 trial that giving patients chemotherapy at the beginning of androgen blockade may improve patient survival...
  10. pmc The current state of preclinical prostate cancer animal models
    Kenneth J Pienta
    University of Michigan, Department of Internal Medicine, Ann Arbor, MI, USA
    Prostate 68:629-39. 2008
    ..It should be possible to apply the knowledge gained molecular and epigenetic studies to develop new cell lines and models that mimic progressive and fatal prostate cancer and ultimately improve interventions...
  11. pmc Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis
    Yao Dai
    Department of Radiation Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0582, USA
    Clin Cancer Res 14:7701-10. 2008
    ..This study aims to investigate the radiosensitizing effect of small-molecule IAP inhibitor both in vitro and in vivo in androgen-independent prostate cancer and the possible mechanism of radiosensitization...
  12. ncbi request reprint Chemotherapy in patients with prostate specific antigen-only disease after primary therapy for prostate carcinoma: a phase II trial of oral estramustine and oral etoposide
    H G Munshi
    Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Cancer 91:2175-80. 2001
    ..This regimen should not be considered standard therapy for the treatment of early recurrent prostate carcinoma, but further exploration of treatment in this setting is warranted...
  13. ncbi request reprint Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer
    K J Pienta
    Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI 48109-0946, USA
    Semin Oncol 28:3-7. 2001
    ..Further elucidation of these differences will be instrumental in designing targeted regimens for the treatment of localized and advanced prostate cancer...
  14. pmc Prostate cancer and parasitism of the bone hematopoietic stem cell niche
    Chunyan Yu
    Department of Urology, School of Medicine, University of Michigan, Ann Arbor, MI 48109 0940, USA
    Crit Rev Eukaryot Gene Expr 22:131-48. 2012
    ..Understanding the concepts of how PCa successfully parasitizes the bone microenvironment is paramount toward identifying therapeutic candidates to prevent or diminish PCa bone metastases...
  15. ncbi request reprint Couples' experiences with prostate cancer: focus group research
    Janet Harden
    College of Nursing, Wayne State University, Detroit, MI, USA
    Oncol Nurs Forum 29:701-9. 2002
    ....
  16. ncbi request reprint Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease
    B T Chen
    Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Urology 65:616-21. 2005
    ....
  17. pmc The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis
    A M Havens
    Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, 1011 North University Ave, Ann Arbor, Michigan 48109 1078, USA
    BMC Cancer 6:195. 2006
    ..CD164 is known to function as a receptor that regulates stem cell localization to the bone marrow...
  18. ncbi request reprint Preferential adhesion of prostate cancer cells to bone is mediated by binding to bone marrow endothelial cells as compared to extracellular matrix components in vitro
    C R Cooper
    Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    Clin Cancer Res 6:4839-47. 2000
    ..These results also strongly demonstrate that the adhesion of prostate cancer cells to bone may be initiated by direct binding to endothelial cells rather than direct binding to exposed ECM components...
  19. ncbi request reprint Prostate carcinoma skeletal metastases: cross-talk between tumor and bone
    E T Keller
    Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, USA
    Cancer Metastasis Rev 20:333-49. 2001
    ..This review focuses on the interaction between the bone and the prostate carcinoma cells that allow for development and progression of prostate carcinoma skeletal metastases...
  20. ncbi request reprint Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
    D C Smith
    Division of Hematology and Medical Oncology, Department of Internal Medicine, University of Michigan School of Medicine, USA
    J Clin Oncol 17:1664-71. 1999
    ..To evaluate the combination of intravenous (IV) paclitaxel, oral estramustine, and oral etoposide in patients with advanced hormone-refractory prostate cancer...
  21. ncbi request reprint Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma
    D L Livant
    Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor 48109 0616, USA
    Cancer Res 60:309-20. 2000
    ..Thus, Ac-PHSCN-NH2 may be a potent antitumorigenic and antimetastatic agent for postsurgical use prior to extensive metastasis...
  22. ncbi request reprint Rapid ("warm") autopsy study for procurement of metastatic prostate cancer
    M A Rubin
    Department of Pathology, University of Michigan, Ann Arbor 48109, USA
    Clin Cancer Res 6:1038-45. 2000
    ..The development and expansion of this program represent a valuable resource for molecular and clinical researchers...
  23. ncbi request reprint Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor"
    H J Muenchen
    Department of Internal Medicine, University of Michigan, Ann Arbor 48109 0946, USA
    Clin Cancer Res 6:1969-77. 2000
    ..It also subsequently decreased IL-6 production by TNF-alpha. We conclude that these data demonstrate that inhibition of NF-kappaB selectively sensitizes previously insensitive prostate cancer cells to TNF-alpha...
  24. ncbi request reprint E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology
    M A Rubin
    Departments of Pathology, Surgery-Urology Section, University of Michigan, Ann Arbor, MI 48109-0054, USA
    Hum Pathol 32:690-7. 2001
    ..Metastatic prostate cancer shows strong E-cadherin expression as determined by anti-E-cadherin antibody HECD-1...
  25. ncbi request reprint Prostate cancer cell adhesion to quiescent endothelial cells is not mediated by beta-1 integrin subunit
    C R Cooper
    University of Michigan Comprehensive Cancer Center, Department of Internal Medicine, Division of Hematology Oncology, Ann Arbor, Michigan 48109, USA
    Anticancer Res 20:4159-62. 2000
    ..The aim of this study was to determine the role beta-1 integrins play in prostate cancer cell adhesion to human bone marrow endothelial cells (HBME) and human aortic endothelial cells (HAEC)...
  26. ncbi request reprint Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
    D C Smith
    Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, USA
    J Clin Oncol 16:1835-43. 1998
    ..Prostate-specific antigen (PSA) has been used as a marker of advanced prostate cancer but remains controversial. To evaluate PSA as a predictor of survival, we analyzed data from sequential phase II trials of estramustine and etoposide...
  27. doi request reprint The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites
    Y Shiozawa
    Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109 1078, USA
    Leukemia 22:941-50. 2008
    ..Further understanding of the interactions between stem cells and the niche may be useful for developing therapeutic strategies...
  28. ncbi request reprint VCaP, a cell-based model system of human prostate cancer
    S Korenchuk
    Departments of Surgery and Internal Medicine, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive-7303 CCGC, Ann Arbor, Michigan 48109-0946, USA
    In Vivo 15:163-8. 2001
    ..We believe that VCaP will be a useful addition to the existing models of prostate cancer, and enable more advanced study of the mechanisms of prostate cancer progression and metastasis...
  29. ncbi request reprint Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3
    H J Muenchen
    Department of Internal Medicine (Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan, USA
    Urology 57:366-70. 2001
    ..CONCLUSIONS: In this study, we demonstrated two distinctly different Taxotere-induced apoptotic pathways in LNCaP and PC-3 cells that may be of clinical importance when treating prostate cancer...
  30. pmc Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
    Yang Meng
    Department of Radiation Oncology, University of Michigan Comprehensive Cancer Center, 4424E Med Sci I SPC5637, 1301 Catherine Street, Ann Arbor, MI 48109 5637, USA
    Mol Cancer Ther 7:2192-202. 2008
    ..Gossypol significantly enhances the antitumor activity of chemotherapy in vitro and in vivo, representing a promising new regime for the treatment of human hormone-refractory prostate cancer with Bcl-2/Bcl-xL/Mcl-1 overexpression...
  31. ncbi request reprint Delineation of prognostic biomarkers in prostate cancer
    S M Dhanasekaran
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 412:822-6. 2001
    ..Thus, the integration of cDNA microarray, high-density tissue microarray, and linked clinical and pathology data is a powerful approach to molecular profiling of human cancer...
  32. pmc Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth
    Jian Zhang
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    J Natl Cancer Inst 102:522-8. 2010
    ..The multiple roles of CCL2 in the tumor microenvironment make it an attractive therapeutic target in metastatic prostate cancer as well as in other cancers...
  33. ncbi request reprint Integrative molecular concept modeling of prostate cancer progression
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nat Genet 39:41-51. 2007
    ..Taken together, these data show that analyzing gene expression signatures in the context of a compendium of molecular concepts is useful in understanding cancer biology...
  34. ncbi request reprint A glycolytic mechanism regulating an angiogenic switch in prostate cancer
    Jianhua Wang
    Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, 1011 North University Avenue, Ann Arbor, MI 48109, USA
    Cancer Res 67:149-59. 2007
    ..These data suggest that PGK1 is a critical downstream target of the chemokine axis and an important regulator of an "angiogenic switch" that is essential for tumor and metastatic growth...
  35. ncbi request reprint Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells
    Yan Xi Sun
    Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109 1078, USA
    Prostate 67:61-73. 2007
    ..Stromal cell-derived factor-1 (SDF-1 or CXCL12) and CXCR4 are key elements in the metastasis of prostate cancer cells to bone--but the mechanisms as to how it localizes to the marrow remains unclear...
  36. pmc CCL2 is a potent regulator of prostate cancer cell migration and proliferation
    Robert D Loberg
    Department of Urology, University of Michigan Urology Center, Ann Arbor, MI 48109 0946, USA
    Neoplasia 8:578-86. 2006
    ..These data suggest that bone marrow endothelial cells are a major source of CCL2, and that an elevated secretion of CCL2 recruits prostate cancer epithelial cells to the bone microenvironment and regulates their proliferation rate...
  37. ncbi request reprint An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone
    Kuei C Lee
    Department of Radiology, and Center for Molecular Imaging, University of Michigan Medical School, 109 Zina Pitcher Place, Ann Arbor, MI 48109, USA
    Cancer Res 67:3524-8. 2007
    ..Validation of fDM results was accomplished by histologic analysis of excised tissue. Results from this study show the capability of fDM as a biomarker for detection of bone cancer treatment efficacy, thus warranting clinical evaluation...
  38. ncbi request reprint Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate
    Niklas J Mackler
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Cancer 106:2617-23. 2006
    ....
  39. ncbi request reprint GREB1 is a novel androgen-regulated gene required for prostate cancer growth
    James M Rae
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Prostate 66:886-94. 2006
    ..GREB1 is expressed in the prostate and its putative promoter contains potential androgen receptor (AR) response elements...
  40. pmc Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo
    Robert D Loberg
    Department of Urology, University of Michigan Urology Center, Ann Arbor, MI, USA
    Neoplasia 8:69-78. 2006
    ..Further investigation into the mechanisms of CD55-mediated tumor cell/microenvironment interaction is necessary to understand the role of CD55 in tumor cell survival and metastatic lesion formation...
  41. ncbi request reprint Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer
    Asmita R Patel
    Sinai Grace Hospital, Detroit Medical Center Wayne State University, MI, USA
    Clin Genitourin Cancer 4:212-4. 2005
  42. ncbi request reprint Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer
    N Lynn Henry
    Department of Internal Medicine, Division of Hematology, University of Michigan School of Medicine, Ann Arbor, Mich, USA
    Oncology 71:168-75. 2006
    ..In tumor models, the copper-chelating agent tetrathiomolybdate (TM) has been shown to be antiangiogenic. We evaluated the antitumor activity of TM in patients with hormone-refractory prostate cancer (HRPC)...
  43. ncbi request reprint A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth
    Qianben Wang
    Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 27:380-92. 2007
    ..These collaborating factors, together with AR, form a regulatory hierarchy that governs androgen-dependent gene expression and prostate cancer growth and offer potential new opportunities for therapeutic intervention...
  44. doi request reprint CCL2 induces prostate cancer transendothelial cell migration via activation of the small GTPase Rac
    Kenneth L van Golen
    Department of Biological Science, Laboratory of Cytoskeletal Physiology, University of Delaware, Newark, Delaware, USA
    J Cell Biochem 104:1587-97. 2008
    ..These data suggest a role for HBME-secreted CCL2 in promoting PCa cell extravasation into the bone microenvironment...
  45. pmc CCL2 protects prostate cancer PC3 cells from autophagic death via phosphatidylinositol 3-kinase/AKT-dependent survivin up-regulation
    Hernan Roca
    Department of Urology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    J Biol Chem 283:25057-73. 2008
    ..Altogether, these findings indicate that CCL2 protects prostate cancer PC3 cells from autophagic death via the phosphatidylinositol 3-kinase/Akt/survivin pathway and reveal survivin as a critical molecule in this survival mechanism...
  46. doi request reprint Novel surface expression of reticulocalbin 1 on bone endothelial cells and human prostate cancer cells is regulated by TNF-alpha
    Carlton R Cooper
    Center for Translational Cancer Research and Department of Biological Sciences, University of Delaware, Newark, Delaware 19716, USA
    J Cell Biochem 104:2298-309. 2008
    ..Taken together, we show cell surface localization of RCN1 that has not been described previously for either PCa or BMEC and that the surface expression on BMEC is regulated by pro-inflammatory TNF-alpha...
  47. pmc Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis
    Christopher L Hall
    Department of Urology, The University of Michigan, Ann Arbor, Michigan, USA
    Prostate 68:1396-404. 2008
    ..We previously demonstrated through over-expression of the Wnt inhibitor dickkopf-1 (DKK-1) that Wnts contribute to the osteoblastic component of PCa osseous lesions in vivo...
  48. pmc An in vivo mouse model for human prostate cancer metastasis
    Aaron M Havens
    Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI 48109, USA
    Neoplasia 10:371-80. 2008
    ..We propose that this new model may be particularly useful in exploring the molecular events in early metastasis, identifying the metastatic niche, and studying issues pertaining to dormancy...
  49. pmc In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration
    Robert D Loberg
    Department of Urology, University of Michigan Urology Center, Ann Arbor, MI, USA
    Neoplasia 9:1030-7. 2007
    ..Inhibition of the antiapoptotic proteins Bcl-2 and Mcl-1 may delay the transition to androgen-independent growth...
  50. pmc A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone
    Kuei C Lee
    Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA
    Neoplasia 9:1003-11. 2007
    ..Thus, the fDM imaging biomarker may provide a quantifiable therapeutic endpoint to assess response in patients with metastatic bone cancer...
  51. ncbi request reprint A polycomb repression signature in metastatic prostate cancer predicts cancer outcome
    Jindan Yu
    Michigan Center for Translational Pathology, Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer Res 67:10657-63. 2007
    ..Therefore, PcG proteins play a central role in the epigenetic silencing of target genes and functionally link stem cells, metastasis, and cancer survival...
  52. ncbi request reprint Randomized clinical trial of a family intervention for prostate cancer patients and their spouses
    Laurel L Northouse
    School of Nursing, University of Michigan, Ann Arbor, Michigan 48109 5482, USA
    Cancer 110:2809-18. 2007
    ....
  53. ncbi request reprint Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo
    Robert D Loberg
    Department of Urology, University of Michigan Urology Center, Ann Arbor, Michigan 48109 0946, USA
    Cancer Res 67:9417-24. 2007
    ..These data suggest an interaction between tumor-derived chemokines and host-derived chemokines acting in cooperation to promote tumor cell survival, proliferation, and metastasis...
  54. pmc CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration
    Robert D Loberg
    Department of Urology, University of Michigan Urology Center, Ann Arbor, MI 48109 0946, USA
    Neoplasia 9:556-62. 2007
    ..These data suggest that CCL2 contributes to prostate cancer growth through the regulation of macrophage infiltration and enhanced angiogenesis within the tumor...
  55. ncbi request reprint Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma
    Niklas J Mackler
    Department of Internal Medicine, Division of Hematology Oncology University of Michigan Medical School
    Clin Genitourin Cancer 5:318-22. 2007
    ..The primary objective of this study was to assess the feasibility and efficacy of administering etoposide/estramustine/paclitaxel in hormone-sensitive metastatic prostate cancer responding to hormonal therapy...
  56. ncbi request reprint Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Cancer Cell 8:393-406. 2005
    ....
  57. pmc Evidence of porcine and human endothelium activation by cancer-associated carbohydrates expressed on glycoproteins and tumour cells
    Olga V Glinskii
    Medical Pharmacology and Physiology Biomedical Sciences Biochemistry, University of Missouri, Columbia, MO 65212, USA
    J Physiol 554:89-99. 2004
    ..Carbohydrate-mediated endothelial activation could be a process of physiological significance as it probably occurs in the interactions between a variety of circulating constituents and the vessel wall...
  58. ncbi request reprint Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma
    Beth Hellerstedt
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Cancer 98:1603-10. 2003
    ..The authors evaluated the combination of oral cyclophosphamide, oral prednisone, and diethylstilbestrol (DES) in patients with androgen-independent prostate carcinoma (AIPC)...
  59. ncbi request reprint The truth is out there: an overall perspective on androgen deprivation
    Beth A Hellerstedt
    Division of Hematology Oncology, University of Michigan Medical Center, 1150 West Medical Center Drive, Box 0640, 5301 MSRB III, Box 0640, Ann Arbor, MI 48109, USA
    Urol Oncol 21:272-81. 2003
    ..At the present time, first-line therapy consists of orchiectomy, LHRH agonists, or combined androgen blockade (CAB). However, new combinations and treatment settings show promise for improving outcomes and decreasing toxicity...
  60. ncbi request reprint Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma
    David C Smith
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Cancer 98:269-76. 2003
    ..The authors conducted this clinical trial to evaluate the addition of carboplatin to the three-drug combination of paclitaxel, estramustine, and etoposide (TEE)...
  61. ncbi request reprint Intravascular metastatic cancer cell homotypic aggregation at the sites of primary attachment to the endothelium
    Vladislav V Glinsky
    Department of Biochemistry, University of Missouri, Columbia, Missouri 65211, USA
    Cancer Res 63:3805-11. 2003
    ....
  62. ncbi request reprint Germ cell tumors: review of selected studies from 2002
    Beth A Hellerstedt
    University of Michigan Medical Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    Curr Opin Oncol 15:234-8. 2003
    ..New chemotherapeutic options are available for patients with platinum-resistant disease, and stem cell transplant remains an area of active study...
  63. ncbi request reprint Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo
    Yan Xi Sun
    Department of Periodontics, Prevention, Geriatrics, University of Michigan School of Dentistry, 1011 North University Ave, Ann Arbor, Michigan 48109 1078, USA
    J Cell Biochem 89:462-73. 2003
    ..These investigations provide important new information pertaining to the molecular basis of how tumors may 'home' to bone, and the mechanisms that may account for their growth in selected end organs...
  64. ncbi request reprint The effect of bone-associated growth factors and cytokines on the growth of prostate cancer cells derived from soft tissue versus bone metastases in vitro
    Hyung Lae Lee
    Chungbuk National University, Cheongju, Korea
    Int J Oncol 22:921-6. 2003
    ..TNF-alpha inhibited proliferation of the VCaP cells. These findings demonstrate that human prostate cancer cell lines derived from bone metastases may not respond preferentially to bone-associated GFs and cytokines...
  65. ncbi request reprint Stromal factors involved in prostate carcinoma metastasis to bone
    Carlton R Cooper
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0946, USA
    Cancer 97:739-47. 2003
    ..Stromal elements in the primary and metastatic target organs are important mediators of tumor cell intravasation, chemoattraction, adhesion to target organ microvascular endothelium, extravasation, and growth at the metastatic site...
  66. ncbi request reprint A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines
    Christopher H Chay
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0946, USA
    Urology 60:760-5. 2002
    ..To identify genes important in prostate cancer metastatic to bone. Bone-specific metastasis is a common feature of prostate cancer and a significant cause of morbidity...
  67. ncbi request reprint The polycomb group protein EZH2 is involved in progression of prostate cancer
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 419:624-9. 2002
    ..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
  68. pmc Suppression of tumor recurrence and metastasis by a combination of the PHSCN sequence and the antiangiogenic compound tetrathiomolybdate in prostate carcinoma
    Kenneth L van Golen
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0948, USA
    Neoplasia 4:373-9. 2002
    ..Improved survival, fewer metastatic lesions, and excellent tolerability were observed with the combination therapy...
  69. pmc MIM, a potential metastasis suppressor gene in bladder cancer
    Young Goo Lee
    Department of Urology, College of Medicine, Hallym University, Seoul, South Korea
    Neoplasia 4:291-4. 2002
    ..We have named this gene Missing in Metastasis (MIM) and our data suggest that it may be involved in cytoskeletal organization...
  70. ncbi request reprint Mind-body effect: insulinlike growth factor-1; clinical depression; and breast, prostate, and other cancer risk-an unmeasured and masked mediator of potential significance?
    Mark A Moyad
    Department of Urology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0330, USA
    Urology 59:4-8. 2002
    ..The time seems ripe to at least define further the relation, if any, between IGF-1 and depression...
  71. ncbi request reprint alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer
    Mark A Rubin
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    JAMA 287:1662-70. 2002
    ..Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens...
  72. ncbi request reprint In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice
    Linda M Kalikin
    Department of Urology, Division of Hematology and Oncology, The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0946, USA
    Cancer Biol Ther 2:656-60. 2003
    ..This model provides a controllable biological system for further investigation into the pathogenesis of metastatic prostate cancer and evaluation of new therapies...
  73. ncbi request reprint The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer
    Rainer Kuefer
    Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0944, USA
    Clin Cancer Res 9:6447-52. 2003
    ..The purpose of this study was to evaluate an 80 kDa proteolytic fragment of E-cadherin as a potential biomarker for prostate cancer progression and to identify putative proteases that are responsible for the cleavage of E-cadherin...
  74. ncbi request reprint Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer
    Robert D Loberg
    Department of Medicine, Michigan Urology Center, University of Michigan, Ann Arbor, Michigan 48109 0946, USA
    Urology 62:128-33. 2003
    ..The decrease in PSADT with disease state may help provide insight into understanding the biology of late-stage disease...
  75. ncbi request reprint Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
    Scott A Tomlins
    Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602, USA
    Science 310:644-8. 2005
    ..These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer...
  76. ncbi request reprint Advances in prostate cancer chemotherapy: a new era begins
    Kenneth J Pienta
    Michigan Urology Center, University of Michigan, Ann Arbor, MI, USA
    CA Cancer J Clin 55:300-18; quiz 323-5. 2005
    ..Building on these advances, several new traditional chemotherapeutic agents as well as new targeted therapies are under development...
  77. ncbi request reprint PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism
    Kwanchanit Tantivejkul
    Department of Urology, The Michigan Urology Center, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Cell Biochem 96:641-52. 2005
    ....
  78. pmc Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells
    Charles J Dimitroff
    Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer Res 65:5750-60. 2005
    ..These findings implicate a functional role of PSGL-1 in the bone tropism of prostate tumor cells and establish a new perspective into the molecular mechanism of human prostate tumor metastasis...
  79. pmc Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs
    Olga V Glinskii
    Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO 65212, USA
    Neoplasia 7:522-7. 2005
    ..Efficient blocking of beta-galactoside-mediated adhesion precludes malignant cell lodging in target organs...
  80. ncbi request reprint Global gene expression profiling of circulating tumor cells
    Denis A Smirnov
    Immunicon Corporation, Huntingdon Valley, Pennsylvania 19006, USA
    Cancer Res 65:4993-7. 2005
    ..Genes such as AGR2, S100A14, S100A16, FABP1, and others were found useful for detection of CTCs in peripheral blood of advanced cancer patients...
  81. ncbi request reprint Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo
    Yan Xi Sun
    Department of Periodontics, Prevention, Geriatrics, University of Michigan School of Dentistry, Ann Arbor, MI 48109 1078, USA
    J Bone Miner Res 20:318-29. 2005
    ..Neutralization of CXCR4 limited the number and the growth of intraosseous metastasis in vivo. Together, these in vivo metastasis data provide critical support that SDF-1/CXCR4 plays a role in skeletal metastasis...
  82. ncbi request reprint Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines
    Sheri Nixdorf
    Oncology Research Centre, Prince of Wales Hospital, Level 2 Clinical Sciences Building, Barker Street, Randwick, NSW 2031, Australia
    Cancer Lett 215:209-20. 2004
    ..Our data also suggest that in those cell lines with reduced levels of MIM and MIM-B mRNA, down-regulation is unlikely to be due to promoter hypermethylation or loss of p53 function...
  83. ncbi request reprint Apoptosis of circulating tumor cells in prostate cancer patients
    Christopher J Larson
    Immunicon Corporation, Huntingdon Valley, PA 19006, USA
    Cytometry A 62:46-53. 2004
    ..The prescence of circulating tumor cells (CTCs) in the peripheral blood of cancer patients and their frequency has been correlated with disease status...
  84. pmc Detection and isolation of circulating tumor cells in urologic cancers: a review
    Robert D Loberg
    Department of Urology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109 0946, USA
    Neoplasia 6:302-9. 2004
    ..The purpose of this review is to present the methods for the detection and isolation of circulating tumor cells and to discuss the importance of circulating tumor cells in the biology and treatment of urologic cancers...
  85. ncbi request reprint Cellular interactions in the tropism of prostate cancer to bone
    Robert A Sikes
    Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA
    Int J Cancer 110:497-503. 2004
    ..Functional integrin association, substratum usage and outside in signaling are more likely to predict metastatic behavior...
  86. ncbi request reprint In vivo real-time imaging of TGF-beta-induced transcriptional activation of the RANK ligand gene promoter in intraosseous prostate cancer
    Jian Zhang
    Department of Pathology and Unit for Laboratory Animal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan, USA
    Prostate 59:360-9. 2004
    ....
  87. ncbi request reprint Cancer cells homing to bone: the significance of chemotaxis and cell adhesion
    Carlton R Cooper
    Department of Biological Sciences, University of Delaware, Newark DE 19716, USA
    Cancer Treat Res 118:291-309. 2004
  88. ncbi request reprint Expression mapping at 12p12-13 in advanced prostate carcinoma
    Adam S Kibel
    Department of Surgery, Division of Urology, Washington University School of Medicine, 4960 Children s Place, St Louis, MO 63110, USA
    Int J Cancer 109:668-72. 2004
    ..DUSP16, FLJ10298 and BCLG were significantly downregulated in both clinical tumors and cultured prostate cancer tissue, indicating that one or all may be critical to initiation or progression of prostate carcinoma...
  89. ncbi request reprint Dynamic process of prostate cancer metastasis to bone
    Kwanchanit Tantivejkul
    Department of Urology, Division of Hematology and Oncology, The Michigan Urology Center at The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, USA
    J Cell Biochem 91:706-17. 2004
    ....
  90. ncbi request reprint The regulation of prostate cancer cell adhesion to human bone marrow endothelial cell monolayers by androgen dihydrotestosterone and cytokines
    Carlton R Cooper
    Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109 0946, USA
    Clin Exp Metastasis 19:25-33. 2002
    ..These results suggest that TGF-beta may reduce tumor cell adhesion to bone marrow microvascular endothelium, in vivo. The biological significance of this observation is discussed...

Research Grants7

  1. The Therapeutic Potential, Pharmacology and Toxiciity of Promising Small-Molecule
    Kenneth Pienta; Fiscal Year: 2005
    ..This will provide the critical impetus to bring the best Bcl-2/xL small-molecule inhibitor to advanced preclinical development and future clinical studies as an entirely new class of cancer therapy...
  2. Molecular Changes Associated with PCa bone metastases
    Kenneth Pienta; Fiscal Year: 2006
    ..This knowledge could lead to the development of better biomarkers of disease progression as well as targets for therapy. ..
  3. S.P.O.R.E. in Prostate Cancer
    Kenneth Pienta; Fiscal Year: 2007
    ..The interaction of our multidisciplinary group of investigators clearly makes the Prostate SPORE program at the UMCCC greater than the sum of its individual parts. ..